Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Formulation, characterization and in-vitro evaluation of solid lipid nanoparticles for the delivery of a new anticancer agent, 1H-pyrazolo[3,4-d] pyrimidine derivative

Amani Elsayed¹ , Amany Belal²

¹Pharmaceutics & Industrial Pharmacy Department, College of Pharmacy; ²Pharmaceutical Chemistry Department, College of Pharmacy, Taif University, Taif 21974, Kingdom of Saudi Arabia.

For correspondence:- Amani Elsayed Email: e.amani@tu.edu.sa Tel:+966567716613

Accepted: 29 April 2021 Published: 30 May 2021

Citation: Elsayed A, Belal A. Formulation, characterization and in-vitro evaluation of solid lipid nanoparticles for the delivery of a new anticancer agent, 1H-pyrazolo[3,4-d] pyrimidine derivative. Trop J Pharm Res 2021; 20(5):885-891 doi: 10.4314/tjpr.v20i5.1

© 2021 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the physicochemical properties and in vitro cytotoxic effect of a potent epidermal growth factor receptor-tyrosine kinase (EGFRWT-TK) inhibitor, 1H-pyrazolo [3,4-d] pyrimidine (FEP) derivative and formulated as solid lipid nanoparticles (SLNs) using stearic acid (ST) or glycerylmonostearate (GMS).

Methods: The SLNs were prepared by hot homogenization and sonication method. The effect of formulation variables on particle size, zeta potential and polydispersity index (PDI) of SLNs were studied, and an optimized formulation selected. Drug-excipient interactions were assessed by differential scanning calorimetry (DSC) and Fourier Transform Infrared (FTIR). Mammary gland breast cancer (MCF-7) and human colon cancer (HCT116) human cell lines were used to evaluate the cytotoxic activity of the free and FEP-loaded SLNs.

Results: The particle size of the SLNs was in the range of 138 - 819 nm, while zeta potential varied from -15 to -20 nm. FEP-loaded SLNs exhibited significant cytotoxic effect compared to the free drug and doxorubicin in the two cell lines (p < 0.05). The activity was higher in HCT116 compared with MCF-7 cells (p < 0.007). The concentration of FEP loaded SLNs, free drug and doxorubicin that showed 50 % inhibition (IC₅₀) for breast cancer cells were 1.06 ± 0.09, 2.58 ± 0.16 and 3.75 ± 0.4 µg/ml, respectively.

Conclusion: The findings show that FEP-loaded SLNs have greater in-vitro cytotoxic activity than the free FEP, and thus, might improve cancer therapy in humans

Keywords: Anticancer, Solid lipid nanoparticles, 1H-pyrazolo[3,4-d] pyrimidine, EGFRWT-TK, Poloxamer 188, Glyceryl monostearate